<?xml version='1.0' encoding='utf-8'?>
<?xml-stylesheet type="text/xsl" href="/v2/static/oai2.xsl"?>
<OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
  <responseDate>2026-10-13T14:04:14Z</responseDate>
  <request identifier="oai:figshare.com:article/33967490" metadataPrefix="oai_dc" verb="GetRecord">https://api.figshare.com/v2/oai</request>
  <GetRecord>
    <record>
      <header>
        <identifier>oai:figshare.com:article/33967490</identifier>
        <datestamp>2026-09-22T17:32:49Z</datestamp>
        <setSpec>category_7</setSpec>
        <setSpec>category_21</setSpec>
        <setSpec>category_45</setSpec>
        <setSpec>category_734</setSpec>
        <setSpec>category_811</setSpec>
        <setSpec>category_106</setSpec>
        <setSpec>portal_5</setSpec>
        <setSpec>item_type_3</setSpec>
        <setSpec>month_year_09_2026</setSpec>
      </header>
      <metadata>
        <oai_dc:dc xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"  xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xmlns:dc="http://purl.org/dc/elements/1.1/" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
          <dc:title>&lt;p&gt;Dataset.&lt;/p&gt;</dc:title>
          <dc:creator>Laban Muteebwa (18784310)</dc:creator>
          <dc:creator>Patience A. Muwanguzi (11914169)</dc:creator>
          <dc:creator>Shivan Nuwasiima (23214428)</dc:creator>
          <dc:creator>Ivan Ahimbisibwe (18784304)</dc:creator>
          <dc:creator>Edson Atwine (23235537)</dc:creator>
          <dc:creator>Dan Muramuzi (17720111)</dc:creator>
          <dc:creator>Cathbert Tumusiime (18784307)</dc:creator>
          <dc:creator>Fred C. Semitala (4386067)</dc:creator>
          <dc:creator>Joanita Nangendo (4386058)</dc:creator>
          <dc:subject>Medicine</dc:subject>
          <dc:subject>Biotechnology</dc:subject>
          <dc:subject>Sociology</dc:subject>
          <dc:subject>Biological Sciences not elsewhere classified</dc:subject>
          <dc:subject>Mathematical Sciences not elsewhere classified</dc:subject>
          <dc:subject>Science Policy</dc:subject>
          <dc:subject>mixed logit model</dc:subject>
          <dc:subject>mean age 19</dc:subject>
          <dc:subject>main effects model</dc:subject>
          <dc:subject>discrete choice experiment</dc:subject>
          <dc:subject>60 %), followed</dc:subject>
          <dc:subject>sd ): 2</dc:subject>
          <dc:subject>based distribution model</dc:subject>
          <dc:subject>based convenience sampling</dc:subject>
          <dc:subject>acquiring hiv living</dc:subject>
          <dc:subject>primary versus secondary</dc:subject>
          <dc:subject>23 )), primary</dc:subject>
          <dc:subject>improving testing coverage</dc:subject>
          <dc:subject>primary delivery channel</dc:subject>
          <dc:subject>based versus community</dc:subject>
          <dc:subject>ci ): 0</dc:subject>
          <dc:subject>primary delivery</dc:subject>
          <dc:subject>secondary delivery</dc:subject>
          <dc:subject>delivery channel</dc:subject>
          <dc:subject>2 %).</dc:subject>
          <dc:subject>17 )),</dc:subject>
          <dc:subject>hiv using</dc:subject>
          <dc:subject>hiv self</dc:subject>
          <dc:subject>young women</dc:subject>
          <dc:subject>urban settings</dc:subject>
          <dc:subject>standard provider</dc:subject>
          <dc:subject>standard deviation</dc:subject>
          <dc:subject>significantly influence</dc:subject>
          <dc:subject>sample type</dc:subject>
          <dc:subject>predicted uptake</dc:subject>
          <dc:subject>optimize uptake</dc:subject>
          <dc:subject>may 2025</dc:subject>
          <dc:subject>marginal utilities</dc:subject>
          <dc:subject>individual attributes</dc:subject>
          <dc:subject>inadequately reached</dc:subject>
          <dc:subject>important attribute</dc:subject>
          <dc:subject>higher risk</dc:subject>
          <dc:subject>designing models</dc:subject>
          <dc:subject>december 2024</dc:subject>
          <dc:subject>crucial innovation</dc:subject>
          <dc:subject>confidence interval</dc:subject>
          <dc:subject>8 years</dc:subject>
          <dc:subject>71 ),</dc:subject>
          <dc:subject>6 ),</dc:subject>
          <dc:subject>24 )).</dc:subject>
          <dc:subject>&amp;# 8217</dc:subject>
          <dc:description>&lt;div&gt;&lt;p&gt;HIV self-testing (HIVST) is a crucial innovation for improving testing coverage, particularly among adolescent girls and young women (AGYW) who are inadequately reached by standard provider-assisted HIV testing approaches. Understanding their preferences for HIVST services is essential for designing models that optimize uptake. We assessed the HIVST preferences among AGYW at a higher risk of acquiring HIV living in urban Uganda. We enrolled AGYW at a higher risk of HIV using a community-based convenience sampling in a discrete choice experiment (DCE). Each participant completed eight choice sets, each comprising of two hypothetical HIVST service alternatives and an opt-out option. The four attributes included level of assistance (assisted versus unassisted), distribution model (facility-based versus community-based), delivery channel (primary versus secondary) and sample type (oral swab versus blood). A mixed logit model was used to estimate the marginal utilities, relative importance (RI), HIVST profile utilities and predicted uptake (compared to opt-out). Between December 2024 and May 2025, 340 participants were enrolled with mean age 19.8 years (standard deviation (SD): 2.6), and 65.9% of them were not in school. In the main effects model, participants preferred; facility-based over community-based distribution model (β = 0.14 (95% confidence interval (CI): 0.06, 0.23)), primary over secondary delivery channel (β = 0.09 (95% CI: 0.00, 0.17)), and unassisted over assisted testing (β = 0.46 (95% CI: 0.37, 0.54). The sample type didn’t significantly influence the preferences of participants to use HIVST (β = 0.05 (95%CI: -0.04, 0.13). The level of assistance emerged as the most important attribute (RI: 60%), followed by facility-based distribution model (RI: 18.9%) and primary delivery channel (RI: 12.2%). There was a significant interaction between delivery channel and level of assistance (β = 0.66 (95% CI: 0.07, 1.24)). Primary delivery was preferred over secondary delivery when testing was unassisted (β = 0.41 (95% CI: 0.11, 0.71), but not when testing was assisted (β = -0.25 (95% CI: -0.56, 0.06). AGYW preferred HIVST models combining primary delivery with unassisted testing while facility-based distribution also increased preference. This highlights the importance of considering both individual attributes and their interaction when designing HIV delivery models.&lt;/p&gt;&lt;/div&gt;</dc:description>
          <dc:date>2026-09-22T17:32:45Z</dc:date>
          <dc:type>Dataset</dc:type>
          <dc:type>Dataset</dc:type>
          <dc:identifier>10.1371/journal.pgph.0005431.s003</dc:identifier>
          <dc:relation>https://figshare.com/articles/dataset/_p_Dataset_p_/33967490</dc:relation>
          <dc:rights>CC BY 4.0</dc:rights>
        </oai_dc:dc>
      </metadata>
    </record>
  </GetRecord>
</OAI-PMH>
